Compare SNAP & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNAP | RDY |
|---|---|---|
| Founded | 2010 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 11.6B |
| IPO Year | 2017 | N/A |
| Metric | SNAP | RDY |
|---|---|---|
| Price | $8.41 | $13.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 26 | 1 |
| Target Price | $10.42 | ★ $16.90 |
| AVG Volume (30 Days) | ★ 34.1M | 1.1M |
| Earning Date | 02-03-2026 | 01-21-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | N/A | ★ 9.95 |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $5,772,269,000.00 | $3,851,623,984.00 |
| Revenue This Year | $12.55 | $6.12 |
| Revenue Next Year | $14.73 | $2.58 |
| P/E Ratio | ★ N/A | $17.45 |
| Revenue Growth | 11.75 | ★ 14.10 |
| 52 Week Low | $6.90 | $12.26 |
| 52 Week High | $13.28 | $16.17 |
| Indicator | SNAP | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 60.36 | 31.09 |
| Support Level | $7.95 | $13.66 |
| Resistance Level | $9.07 | $14.12 |
| Average True Range (ATR) | 0.27 | 0.17 |
| MACD | 0.10 | -0.07 |
| Stochastic Oscillator | 59.63 | 1.05 |
Snap is a technology company best known for its marquis social media application. Snapchat, a visual messaging application that has amassed hundreds of millions of users. The app was initially only used to communicate with family and friends through photographs and short videos (known as "Snaps"). Users can now enjoy augmented reality, or AR, lenses, content from famous creators and celebrities, updates about local events, and more. Although the app offers a paid subscription option with premium features, advertising sales produce most of the app's revenue. The firm also sells wearable devices called AR Spectacles, which can capture photos and videos overlayed with AR lenses, but these make up a small portion of Snap's overall sales.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.